new
emerg
infecti
diseas
continu
plagu
world
signific
concern
recombin
infecti
agent
use
bioterror
threat
microbiologist
increasingli
ask
appli
scientif
knowledg
respond
threat
recent
pandem
caus
sever
acut
respiratori
syndrom
sar
coronaviru
illustr
newli
evolv
pathogen
rapidli
spread
throughout
world
also
global
commun
unit
identifi
caus
agent
control
spread
rapid
respons
research
mechan
use
sar
acceler
vaccin
initi
savi
shown
applic
emerg
manag
techniqu
togeth
rapid
respons
research
highli
effect
appli
appropri
new
infecti
diseas
throughout
human
histori
infecti
diseas
import
role
shape
evolv
world
pandem
epidem
commonplac
densiti
world
popul
intern
travel
trade
increas
support
global
spread
pathogen
microbi
pathogen
constantli
evolv
new
pathogen
continu
emerg
natur
recent
emerg
mani
new
pathogen
includ
hiv
enterohaemorrhag
escherichia
coli
west
nile
viru
legionella
pneumophila
cryptococcu
neoforman
subspeci
gattii
variou
influenza
strain
actual
biolog
take
normal
cours
microorgan
evolv
exploit
new
alter
ecolog
nich
therefor
surpris
first
pandem
twentyfirst
centuri
appear
quickli
late
sever
acut
respiratori
syndrom
coronaviru
sarscov
caus
signific
morbid
approxim
case
mortal
death
estim
econom
impact
us
billion
worldwid
sar
outbreak
provid
excel
opportun
attempt
har
power
modern
scienc
provid
rapid
solut
public
health
emerg
place
pressur
mani
microbiologist
worldwid
identifi
sequenc
viru
character
diseas
appli
modern
epidemiolog
techniqu
track
trace
viru
origin
develop
strategi
treat
control
pathogen
worldwid
scientist
respond
challeng
extrem
vigour
mani
achiev
made
fig
includ
identifi
caus
agent
sequenc
genom
develop
anim
model
infect
determin
pathogen
origin
natur
global
spread
human
commun
howev
despit
acquisit
larg
bodi
scientif
inform
sar
spread
around
world
method
control
viru
requir
case
escap
contain
measur
meant
altern
therapeut
prevent
method
urgent
need
develop
vaccin
therapeut
agent
usual
take
least
decad
cost
hundr
million
dollar
yet
practic
solut
sar
need
begin
next
respiratori
viru
season
addit
new
microbi
threat
like
emerg
scientist
ask
provid
rapid
solut
fast
success
respons
sar
could
provid
exampl
scienc
effect
appli
respons
new
emerg
diseas
unfortun
usual
scientif
process
design
focus
quickli
solv
practic
problem
grant
applic
peer
review
fund
mechan
tradit
rapid
process
respond
emerg
infecti
diseas
press
public
health
import
requir
scientif
process
significantli
differ
tradit
procedur
respons
must
focu
scienc
directli
practic
solut
problem
solv
sever
scientif
problem
parallel
instead
sequenc
sar
pandem
provid
perfect
opportun
attempt
develop
system
clinic
trial
regulatori
affair
intern
collabor
develop
parallel
instead
sequenti
soon
genom
becam
avail
bioinformat
web
site
creat
use
savi
scientist
well
mani
sar
research
around
world
see
sar
bioinformat
suit
onlin
link
box
addit
larg
demand
worldwid
fulllength
sequenc
clone
variou
sar
coronaviru
gene
sever
programm
put
place
clone
express
viral
protein
could
use
reagent
vaccin
studi
method
develop
grow
viru
tissu
cultur
use
vero
cell
neutral
assay
develop
necessari
vaccin
develop
import
factor
produc
vaccin
quickli
earli
avail
inform
basi
immunolog
protect
diseas
although
immun
correl
protect
sarscov
yet
complet
defin
individu
convalesc
sar
known
develop
high
titr
neutral
antibodi
appear
neutral
antibodi
coincid
onset
resolut
sar
pneumonia
coronavirus
invers
relationship
diseas
sever
level
preexist
serum
antibodi
neutral
antibodi
like
import
protect
sar
tcell
immun
also
like
necessari
protect
sar
mani
virus
instanc
low
concentr
cell
sar
infect
correl
increas
diseas
sever
mortal
specif
human
leukocyt
antigen
hla
class
allel
correl
sar
suscept
taken
togeth
data
indic
vaccin
sar
would
need
induc
neutral
antibodi
possibl
tcell
respons
knowledg
prove
help
select
vaccin
candid
immun
approach
mani
potenti
vaccin
strategi
consid
sarscov
includ
whole
kill
viral
vaccin
attenu
viru
adenoviru
vaccinia
viru
express
sar
protein
recombin
sar
protein
dna
vaccin
success
vaccin
develop
anim
coronavirus
indic
one
strategi
might
work
inform
sar
protein
could
use
candid
vaccin
antigen
also
obtain
develop
anim
coronaviru
vaccin
emerg
sar
mani
scientif
group
worldwid
began
studi
diseas
canada
particularli
affect
sarsther
case
death
world
health
organ
travel
health
advisori
issu
therefor
strong
interest
pandem
michael
smith
genom
scienc
centr
vancouv
emerg
manag
plan
place
allow
entir
facil
dedic
rapid
sequenc
infecti
agent
collabor
british
columbia
centr
diseas
control
health
suppli
sar
clinic
viru
strain
known
toronto
centr
gener
first
genom
sequenc
sarscov
within
six
day
receiv
viral
nucleic
acid
sever
group
follow
genom
sequenc
shortli
thereaft
key
sequenc
genom
quickli
rapid
respons
emerg
manag
plan
alreadi
place
entail
topdown
manag
approach
taken
team
member
parallel
project
abl
dedic
time
expertis
assign
task
success
coupl
concern
canada
quarantin
would
contain
sarscov
led
provinci
british
columbia
govern
provid
cdn
million
april
establish
sar
acceler
vaccin
initi
savi
dedic
develop
human
sar
vaccin
rapidli
possibl
vaccin
approach
chosen
sever
reason
includ
previou
success
anim
coronaviru
vaccin
eas
product
develop
use
vaccin
prevent
infect
case
defin
risk
exposur
healthcar
worker
hospit
savi
establish
appli
rapid
respons
research
public
health
issu
design
one
goal
develop
safe
effect
human
sar
vaccin
rapidli
possibl
savifund
vaccinedevelop
initi
evalu
goal
mind
senior
manag
committe
establish
signific
expertis
anim
coronaviru
vaccin
epidemiolog
clinic
trial
grantfund
mechan
emerg
manag
strategi
adopt
weekli
teleconfer
member
well
regular
manag
committe
discuss
parallel
research
strategi
design
vaccin
develop
ultim
goal
addit
identifi
vaccin
candid
immunolog
assay
intellectu
properti
success
commerci
vaccin
strong
intellectu
properti
posit
need
savi
fortun
partner
group
sequenc
sarscov
protect
genom
sequenc
howev
addit
intellectu
properti
issu
aris
project
progress
also
preexist
intellectu
properti
place
must
incorpor
use
live
attenu
vector
protein
express
system
savi
decid
make
legal
entiti
leav
ownership
intellectu
properti
inventor
home
univers
save
signific
time
intellectu
properti
mechan
alreadi
establish
variou
partner
univers
issu
royalti
rate
alreadi
settl
appropri
way
deal
intellectu
properti
remain
signific
challeng
worldwid
develop
commerci
sar
vaccin
regulatori
issu
regulatori
issu
anoth
consider
rapidli
develop
vaccin
vaccin
often
take
mani
year
develop
yet
need
sar
vaccin
urgent
begin
initi
discuss
held
appropri
regulatori
bodi
health
canada
us
fda
gain
support
obtain
document
describ
regulatori
guidelin
biolog
agent
addit
savi
work
regulatori
author
consult
defin
step
need
vaccin
develop
includ
use
clinic
approv
cell
line
vaccin
gener
avoid
anim
product
vaccin
product
identif
plasmid
anoth
import
consider
vaccin
test
avail
relev
anim
infect
challeng
model
vaccin
studi
initi
anim
model
avail
assum
would
develop
quickli
rapid
vaccin
develop
ultim
goal
decid
assum
becam
avail
initi
test
vaccin
candid
relev
anim
infect
model
possibl
nonhuman
primat
smallanim
vaccin
model
mislead
time
consum
soon
macaqu
infect
model
publish
signific
effort
made
secur
primat
studi
howev
recent
signific
concern
primat
model
best
infect
model
test
mani
laboratori
indic
exhibit
mild
respiratori
infect
present
ferret
seem
relev
diseas
model
relev
murin
model
develop
allow
viral
replic
owe
high
cost
primat
experi
biosafeti
level
iii
contain
facil
concern
relev
primat
challeng
model
present
savi
vaccin
first
test
ferret
mice
nonhuman
primat
small
anim
safeti
immunogen
similarli
group
test
adenovirus
modifi
vaccinia
virus
dna
vaccin
murin
macaqu
model
although
addit
step
add
time
project
necessari
imper
show
protect
anim
infect
model
close
mimic
human
diseas
anticip
test
multipl
anim
model
would
also
help
elimin
concern
regard
vaccineinduc
immun
enhanc
immunopatholog
addit
fundament
scientif
question
associ
vaccin
develop
sever
relat
issu
impact
directli
success
project
fig
includ
spike
surfac
glycoprotein
found
viral
surfac
give
viral
particl
crown
therefor
name
nucleocapsid
n
protein
found
insid
viral
particl
packag
rna
viral
genom
fig
decid
antigen
vaccin
approach
use
pose
signific
challeng
advantag
disadvantag
research
group
chose
particular
vaccin
method
familiar
contrast
savi
chose
develop
three
vaccin
approach
parallel
make
final
decis
candid
progress
human
clinic
trial
direct
comparison
three
vaccin
relev
anim
infect
model
strategi
also
provid
opportun
use
one
vaccin
primeboost
strategi
necessari
although
approach
initi
requir
work
thought
would
significantli
increas
likelihood
success
vaccin
develop
work
began
three
strategi
develop
whole
kill
inactiv
viru
develop
recombin
protein
modifi
adenoviru
vaccinia
viru
express
sarscov
n
protein
whole
kill
viru
recombin
protein
target
induc
neutral
antibodi
wherea
adenoviru
vaccinia
viru
vector
target
induc
cellular
immun
neutral
antibodi
prove
import
bring
togeth
dispar
research
commun
common
effort
research
obtain
fund
still
held
account
standard
grant
regul
research
guidelin
includ
adequ
account
report
complet
project
project
director
period
review
progress
fund
collabor
ensur
adequ
progress
relev
well
coordin
divers
research
group
intern
collabor
vaccin
develop
sar
pandem
intern
coordin
collabor
essenti
import
role
coordin
respons
follow
epidem
addit
octob
host
meet
geneva
attend
nearli
main
research
group
work
sarscov
sar
vaccin
meet
use
mani
respect
includ
allow
variou
group
discuss
strategi
progress
resolv
intellectu
properti
regulatori
issu
select
develop
anim
model
sever
addit
collabor
form
meet
well
better
understand
world
stood
regard
vaccin
recent
februari
held
meet
rotterdam
reach
consensu
regard
anim
model
repres
best
infect
model
test
sar
vaccin
candid
although
macaqu
model
describ
sar
still
question
regard
suitabl
vaccin
test
least
three
north
american
laboratori
littl
success
observ
lung
patholog
sever
clinic
sign
macaqu
live
sarscov
challeng
factor
dose
strain
sarscov
rout
administr
day
autopsi
might
account
variabl
laboratori
consensu
meet
rotterdam
standard
condit
sarscov
challeng
need
differ
laboratori
nonhuman
primat
could
use
vaccin
test
strain
mice
balbc
shown
support
sarscov
replic
demonstr
signific
patholog
clinic
diseas
smallanim
model
sar
ferret
hamster
unpublish
observ
meet
rotterdam
ref
also
support
viral
replic
demonstr
level
patholog
similar
human
anim
offer
canada
unit
state
extrem
support
will
work
accord
riskbenefit
platform
sar
develop
next
major
pandem
would
done
everyth
possibl
expedit
approv
process
counter
risk
diseas
sar
current
major
threat
agre
normal
regulatori
approv
mechan
appli
expedit
vaccin
approv
might
unnecessari
handl
media
major
diseas
outbreak
receiv
signific
media
attent
continu
demand
updat
research
progress
potenti
therapeut
prevent
vaccin
therefor
mechan
need
place
deal
respons
media
request
project
progress
consequ
system
establish
enabl
effect
commun
media
need
provid
consist
messag
handl
expand
expect
provid
import
messag
progress
project
media
brief
also
provid
everi
six
month
scientif
symposia
held
everi
six
month
keep
entir
savi
group
collabor
abreast
progress
made
differ
area
project
fund
mechan
import
hurdl
rapid
respons
research
distribut
fund
research
time
manner
timefram
start
write
peerreview
grant
applic
fund
receiv
laboratori
usual
one
year
unsuit
rapid
respons
research
rapid
fund
mechan
must
establish
ensur
appropri
research
carri
time
manner
savi
establish
michael
smith
foundat
health
research
provinci
health
research
fund
agenc
british
columbia
use
control
dispens
research
fund
use
fivememb
senior
manag
committe
consist
senior
scientist
rapid
review
mechan
establish
short
focus
research
propos
togeth
propos
research
budget
dealt
directli
aspect
vaccin
develop
solicit
accept
research
commun
committe
review
evalu
project
basi
scientif
merit
direct
need
project
fund
dispers
success
applic
immedi
usual
hour
applic
submit
ensur
applic
peerreview
rapid
review
process
significantli
enhanc
speed
project
natur
review
microbiolog
volum
juli
infecti
diseas
exemplifi
sar
patient
consent
clinic
sampl
taken
especi
earli
outbreak
potenti
research
use
sampl
known
difficult
specifi
exactli
use
howev
larg
collect
clinic
sampl
crucial
understand
infecti
diseas
mechan
collect
share
sampl
must
place
outbreak
occur
vaccin
therapeut
product
use
human
clinic
trial
made
stringent
gmp
ideal
rapid
respons
research
would
done
condit
start
nearli
imposs
especi
infecti
agent
instead
candid
vaccin
therapeut
identifi
work
reproduc
condit
significantli
lengthen
product
time
outset
standard
cell
line
vero
cell
attenu
viral
vector
adenoviru
adjuv
alum
chosen
alreadi
approv
human
use
signific
time
save
product
develop
sar
particularli
challeng
requir
biosafeti
level
iii
contain
anim
studi
must
done
stringent
contain
facil
world
similarli
whole
kill
viral
vaccin
manufactur
highli
special
biosafeti
level
iii
gmp
facil
need
exist
worldwid
owe
perceiv
threat
biolog
agent
sever
biosafeti
level
iii
contain
facil
recent
approv
construct
howev
perform
rapid
respons
research
highli
infecti
agent
new
world
place
major
burden
special
facil
especi
biosafeti
level
iii
larg
anim
primat
gmp
facil
effici
use
space
requir
global
cooper
judici
priorit
commerci
commerci
sar
vaccin
rais
sever
complex
issu
seem
sar
worldwid
threat
present
signific
commerci
market
vaccin
compani
unwil
spend
hundr
million
dollar
need
commerci
vaccin
unlik
recov
expens
sever
reason
industri
unwil
commit
develop
specif
vaccin
first
huge
cost
vaccin
develop
us
million
small
uncertain
revenu
tradit
vaccin
made
vaccin
manufactur
abil
rapid
research
respons
emerg
infecti
diseas
signific
appeal
sar
seen
major
public
health
threat
canada
sever
countri
asia
countri
particular
felt
compel
act
canada
indic
concept
work
togeth
rapid
respons
research
toward
sar
vaccin
rapidli
accept
research
approach
fact
scholar
nonlifesci
area
academia
also
freeli
offer
time
skill
deal
relat
problem
scientist
will
contribut
relev
expertis
portion
laboratori
resourc
work
toward
common
goal
particular
individu
gain
immedi
obviou
although
willing
probabl
accentu
one
perceiv
signific
threat
one
countri
also
power
motiv
factor
seek
obtain
particular
expertis
rapid
respons
research
similarli
intern
cooper
coordin
need
avoid
signific
duplic
redund
effort
well
share
progress
ideal
situat
expertis
around
world
would
coordin
pose
major
logist
polit
challeng
pivot
role
throughout
sar
pandem
track
diseas
also
conven
meet
research
work
potenti
vaccin
therapeut
diagnost
face
futur
pandem
coordin
intern
rapid
respons
research
approach
essenti
develop
new
way
control
scourg
main
difficulti
sar
research
limit
avail
clinic
sampl
research
standard
sampl
countri
nation
centr
diseas
control
collect
coordin
clinic
sampl
wherea
other
left
individu
hospit
import
problem
studi
emerg
altern
inexpens
diseas
model
compar
nonhuman
primat
although
report
use
small
anim
sarscov
vaccin
test
scarc
howev
despit
differ
anim
model
singl
anim
speci
shown
reproduc
clinic
sign
lethal
observ
human
infect
sarscov
anticip
reemerg
sar
would
like
occur
close
origin
site
origin
savi
initi
collabor
chines
scientist
guangdong
provinc
southern
china
result
bilater
agreement
work
togeth
sar
vaccin
trial
collabor
greatli
facilit
strong
polit
support
china
canada
two
countri
significantli
affect
sar
obviou
question
sar
vaccin
evalu
human
efficaci
given
lack
human
sar
case
global
year
ordinarili
phase
phase
iii
human
clinic
trial
design
provid
understand
safeti
immunogen
vaccin
human
well
identif
correl
immun
without
outbreak
sar
could
use
test
efficaci
vaccin
human
licensur
vaccin
emerg
condit
might
take
place
fda
anim
efficaci
rule
state
vaccin
biolog
agent
licens
meet
two
criteria
human
safeti
demonstr
adequ
protect
deliber
infect
challeng
two
speci
anim
see
vaccin
polici
onlin
link
sar
vaccin
go
directli
anim
human
condit
vaccin
efficaci
safeti
must
evalu
anim
follow
phase
safeti
evalu
immunogen
test
healthi
human
volunt
phase
studi
current
ongo
china
inactiv
sar
viru
present
enough
sar
case
test
vaccin
phase
ii
iii
trial
despit
lack
ongo
sar
threat
rapid
respons
initi
savi
continu
necessari
import
vaccin
avail
sar
return
furthermor
initi
strongli
support
intern
recogn
scientist
strong
expertis
particular
area
research
develop
contrast
pharmaceut
compani
product
focu
diffus
expertis
suitabl
gmp
vaccin
manufactur
organ
clinic
trial
human
concept
work
togeth
rapid
respons
research
toward
sar
vaccin
rapidli
accept
research
approach
scientist
will
work
toward
common
goal
